JP2019519491A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519491A5
JP2019519491A5 JP2018558662A JP2018558662A JP2019519491A5 JP 2019519491 A5 JP2019519491 A5 JP 2019519491A5 JP 2018558662 A JP2018558662 A JP 2018558662A JP 2018558662 A JP2018558662 A JP 2018558662A JP 2019519491 A5 JP2019519491 A5 JP 2019519491A5
Authority
JP
Japan
Prior art keywords
compound
compound according
groups
formula
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018558662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519491A (ja
JP6946342B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031696 external-priority patent/WO2017196806A1/en
Publication of JP2019519491A publication Critical patent/JP2019519491A/ja
Publication of JP2019519491A5 publication Critical patent/JP2019519491A5/ja
Application granted granted Critical
Publication of JP6946342B2 publication Critical patent/JP6946342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018558662A 2016-05-09 2017-05-09 エバンスブルー誘導体の化学的コンジュゲート、ならびに放射線治療剤およびイメージング剤としてのそれらの使用 Active JP6946342B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333427P 2016-05-09 2016-05-09
US62/333,427 2016-05-09
PCT/US2017/031696 WO2017196806A1 (en) 2016-05-09 2017-05-09 Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents

Publications (3)

Publication Number Publication Date
JP2019519491A JP2019519491A (ja) 2019-07-11
JP2019519491A5 true JP2019519491A5 (enExample) 2020-05-28
JP6946342B2 JP6946342B2 (ja) 2021-10-06

Family

ID=60267260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018558662A Active JP6946342B2 (ja) 2016-05-09 2017-05-09 エバンスブルー誘導体の化学的コンジュゲート、ならびに放射線治療剤およびイメージング剤としてのそれらの使用

Country Status (6)

Country Link
US (1) US10696631B2 (enExample)
EP (1) EP3455206B1 (enExample)
JP (1) JP6946342B2 (enExample)
CN (1) CN109153641B (enExample)
SG (1) SG11201809982RA (enExample)
WO (1) WO2017196806A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709790B2 (en) 2015-06-22 2020-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of Evans Blue derivatives and their use in the production of long-acting therapeutics
EP3692032B1 (en) 2017-10-03 2024-06-19 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
WO2019165200A1 (en) 2018-02-22 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
TWI745616B (zh) * 2018-09-10 2021-11-11 行政院原子能委員會核能研究所 放射線標誌長效型靶向性胜肽藥物及其生產方法
CN109485642A (zh) * 2018-11-21 2019-03-19 希施生物科技(上海)有限公司 一种制备伊文氏蓝衍生物的方法
WO2020160222A2 (en) 2019-01-30 2020-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Conjugates of bivalent evans blue dye derivatives and methods of use
US12357712B2 (en) * 2019-05-24 2025-07-15 Beijing Giluntide Pharmaceutical Co., Ltd. Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy
TWI908773B (zh) * 2020-03-04 2025-12-21 日商日本醫事物理股份有限公司 化合物及放射性標誌化合物
JP7894086B2 (ja) * 2020-05-06 2026-07-23 コーネル ユニヴァーシティー 銅含有セラグノスティック化合物及びその使用の方法
CN114790193B (zh) * 2020-12-21 2024-05-10 苏州药明博锐生物科技有限公司 成纤维细胞活化蛋白抑制剂
CA3210863C (en) 2021-02-10 2024-06-04 Yantai Lannacheng Biotechnology Co., Ltd. Truncated evans blue modified fibroblast activation protein inhibitor, preparation method and application thereof
CN114369084B (zh) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CN113004371A (zh) * 2021-03-01 2021-06-22 上海蓝纳成生物技术有限公司 一种长循环半衰期的前列腺特异性膜抗原靶向化合物及其制备方法和应用
CN114796532A (zh) * 2022-04-20 2022-07-29 北京先通国际医药科技股份有限公司 放射性标记的伊文思蓝衍生物药物水溶液及其用途
AU2023283882A1 (en) * 2022-06-10 2025-01-30 Peking University Trifunctional compound and use thereof
CN115433261B (zh) * 2022-11-07 2023-01-13 烟台蓝纳成生物技术有限公司 一种rgd二聚体化合物及其制备方法和应用
CN115583989B (zh) * 2022-12-09 2023-02-28 烟台蓝纳成生物技术有限公司 一种靶向sstr2的化合物及其制备方法和应用
CN115611779A (zh) * 2022-12-21 2023-01-17 北京先通国际医药科技股份有限公司 一种放射性药物前体的中间体的制备方法及其用途
CN115838393B (zh) * 2023-02-16 2023-05-05 烟台蓝纳成生物技术有限公司 用于fapi合成的中间体及其制备方法和应用
CN115850367B (zh) * 2023-03-02 2023-05-23 北京先通国际医药科技股份有限公司 Psma抑制剂的纯化方法及其用途
CN115947775B (zh) * 2023-03-13 2023-06-09 北京先通国际医药科技股份有限公司 一种制备化合物(i)的方法和化合物(i)及其用途
KR20260009883A (ko) * 2023-05-24 2026-01-20 베이징 창핑 래보러토리 신규 삼관능 화합물 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1598082A4 (en) 2003-02-27 2008-11-12 Univ Kyushu Nat Univ Corp CONTRASTANT FOR NUCLEAR PENTOMOGRAPHY
JPWO2006025304A1 (ja) 2004-08-30 2008-05-08 国立大学法人九州大学 動脈硬化検知用mri造影剤
US20110223102A1 (en) * 2007-09-14 2011-09-15 Health Research, Inc. Multimodality agents for tumor imaging and therapy
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
CN101623504A (zh) * 2008-07-07 2010-01-13 中国人民解放军军事医学科学院放射与辐射医学研究所 伊文思蓝作为实体肿瘤着色剂的用途
CN103242255B (zh) * 2013-04-28 2015-01-14 厦门大学 伊文氏蓝配合物及其制备方法和应用
CN104650217B (zh) * 2015-01-26 2018-08-10 莎穆(上海)生物科技有限公司 伊文氏蓝或其衍生物修饰的Exendin-4及其制备方法和应用
US20160287730A1 (en) 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
US10709790B2 (en) * 2015-06-22 2020-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of Evans Blue derivatives and their use in the production of long-acting therapeutics
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
EP3692032B1 (en) 2017-10-03 2024-06-19 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
WO2019165200A1 (en) 2018-02-22 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer

Similar Documents

Publication Publication Date Title
US10238630B2 (en) Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
KR20200116477A (ko) 플리나불린 및 g-csf 제제의 투여를 통해 화학요법-유도된 호중구감소증을 감소시키기 위한 조성물 및 방법
ES2946472T3 (es) Agente antitumoral y potenciador del efecto antitumoral
JP2019510832A5 (enExample)
JP2017528498A5 (enExample)
CN105338977A (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
JP2011529919A5 (enExample)
JP2015522650A5 (enExample)
EP2275107A3 (en) Combinations for the treatment of diseases involving cell proliferation
RU2020107416A (ru) Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака
JP2017521486A5 (enExample)
JP2014532716A5 (enExample)
JP2015502926A5 (enExample)
JP2013521291A5 (enExample)
JP2010507593A5 (enExample)
JP2020531593A5 (enExample)
RU2007105233A (ru) Производные порфирина и их применение в фотонно-активационной терапии
JP2012522841A5 (enExample)
JP6469077B2 (ja) 4−アミノ−2−(2,6−ジオキソ−ピペリジン3−イル)−イソインドリン−1,3−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物
JP2013511526A5 (enExample)
US20100196363A1 (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
JP2009534418A5 (enExample)
RU2017119660A (ru) Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения
EP4591940A3 (en) Deoxy- cytidine derivatives for use in cancer therapies